|
Post by shortslaver on Jan 27, 2015 18:13:46 GMT -5
Rumor that Cramer now says MNKD is a BUY! If Cramer talks about Mannkind as a BUY on his show, that may indeed start the short squeeze. Don't think I've ever participated in one. This could be fun indeed! I owned a ton of TSLA a few years ago before it went crazy. Part of it was because a product that previously failed was launched that was going to be successful so everyone wanted to be a part of it. The other reason was that the short interest was so high it just kept propelling the stock up and up for many, many months. My advice is this: Nothing goes straight up. It will have wild up days and wild, awful down days. But if the product is successful then it will only trend up for a long while. Buy the dips instead of dumping during dips then.
|
|
|
Post by 4allthemarbles on Jan 27, 2015 21:43:27 GMT -5
Rumor that Cramer now says MNKD is a BUY! Why is that such a suprise? Cramer has been a supporter of MNkD for years now? Don't you remember? He loves us. Kind of of reminds me of that time he was on Good Morning America or the today show where they played those clips of him telling everyone that Bear Sterns was fine. Oh, Cramer... What will you think of next?
|
|
|
Post by EveningOfTheDay on Jan 27, 2015 21:49:31 GMT -5
Good finish to an article where the interviewer started with the ghost of Exubera. Maybe to just put it finally to rest. it would be about time.
|
|
|
Post by kc on Jan 28, 2015 9:52:37 GMT -5
Hi volume for today first 15 mins over 1,000,000 shares. Enough for Dow Jones Market watch to notice. Is there a fire burning? The best is yet to come.
|
|
|
Post by kc on Jan 28, 2015 11:22:46 GMT -5
From an Italian press site this morning. Sorry for the poor translation and formating. www.webnews.it/2015/01/28/tecnosfere-afrezza-diabete/Afrezza is an innovative medicine that leveraging Technosphere result of research MannKind , allows the absorption of insulin by inhalation . 1. Could start everything from a small pipette for easy inhalation : his name is Afrezza and at this time is the great hope in the hands of the US MannKind and its shareholders . But hope , beyond the mere computation economic / financial , but also and especially for the world of diabetics . Afrezza, in fact , could be a real revolution for those who have the need for insulin injections : just needles , stop headroom and embarrassment and open road to a simple tool that improves , speeds up and makes more efficient operation . 2. 3. Afrezza and technosphere 4. Everything is based on so-called Technosphere , crystalline micro particles that represent the essence of biomedical research of MannKind . The great innovation that allows this type of technology is the ability to inhale a drug instead of launching the absorption by injection or by ingestion . Inhalation makes for fast absorption and action of the medicine , but it also makes it much easier to do the same . All this , even more so , for those suffering from diabetes and has the need to constantly monitor their situation to take urgent action in case of need Besides diabetes But behind the Technosphere there is much more. Afrezza, in fact, could be a simple platform on which to test the quality of research MannKind. The model, in fact, is potentially applicable to a high number of cases and medicines, which would mean a leap bully in the way that the medicine can intervene in a large number of situations. The Technosphere, in short, could represent a revolution if only these first steps in the world of diabetes should return the desired results. For this there is great attention to the name and on MannKind to Afrezza: patents on guard the hopes of many and a potential leap in the quality of life of millions of people around the world. If you want updates on Afrezza: the revolution of diabetes?, enter your e-mail in the box below:
|
|
|
Post by savzak on Jan 28, 2015 14:00:17 GMT -5
I think we'll be seeing a lot of this from now on. No new information, just new interest. Let the buzz begin...
phlauntdiabetesupdates.blogspot.com/2015/01/afrezza-super-fast-acting-inhaled.html
Wednesday, January 28, 2015
Afrezza, Super fast-acting inhaled insulin now on Sale. Afrezza page added to Blood Sugar 101
Afrezza A New Extremely Fast-Acting Inhaled Insulin
Afrezza became available in pharmacies on January 26, 2015. It is being covered at a non-preferred tier by quite a few insurers and should be coming to more within the next year. Afrezza is a brand new inhaled insulin. Readers who have followed my blog know that I was very negative on the first inhaled insulin, Exubera. That was because it was extremely hard to dose and did not appear to be as good as injected insulin.
I have been following the Afrezza story for about a year, and am cautiously hopeful that, unlike Exubera, Afrezza will be a much more useful product.
That isn't just because it's inhaled rather than injected. That's a nice feature that will appeal to the many people with Type 2 who really need insulin but won't start it out of misguided fear of needles. Insulin needles are painless when prescribed correctly. So this is not a good reason to avoid insulin. But people do. We all know far too many people who fit that category. Many end up on dialysis or with amputations.
So Afrezza will be good for needlephobes. But what really excites me about Afrezza is its activity curve. It is different from all the existing injected insulins and does something that no other drug does. To understand what that is, you need to understand how our bodies normally produce insulin, in two distinct phases. You can read more about this HERE. All the current injected insulins replace second phase insulin production. They take about an hour to start working and several more to exit the body. But Afrezza appears to replace first phase insulin production which just happens to be the part of insulin production that disappears first. People diagnosed with Type 2 diabetes have usually lost all their first phase insulin production while retaining a lot of their second phase capability.
This means it might be an excellent drug for people recently diagnosed and one that is much safer than the drugs like Januvia or Victoza many are being put into at that time, whose dangers I have discussed elsewhere.
One major problem with injected insulin is that it takes a long time to exit the body. This means that you can still have insulin working a couple hours after you have finished digesting your meal. This can cause hypos and makes doctors dose fast-acting insulin very conservatively. They don't give you enough to really cover your meal because of the fear that the lingering insulin will cause lows. But because Afrezza leaves the body much more quickly, you may be able to take a larger dose that will lower your blood sugar post-meal much better, knowing it will be gone right after it lowered your blood sugar.
The above is based on the claim made by the drug company that makes Afrezza and it is supported by activity curve graph published in the prescribing information which you can see in the graph to the right:
Lispro, which is what Afrezza is being compared to here, is Humalog.
Afrezza comes in cartridges that you put into the small inhaler, inhale, and throw away. The inhaler does not need to be cleaned. Every two weeks you throw out the inhaler and use the second one that comes with the cartridges.
The doses come in cartridges sold in increments of 4 units. Because of the fast way Afrezza operates, it may be possible to use a significantly larger dose than you would use if you were injecting a slower fast-acting insulin. The prescribing information makes it sound like 4 units would be appropriate for anyone using up to 4 units of injected insulin. Whether this is true we will only know after we hear from people who report their results.
What makes me feel that I can trust the company that makes Afrezza, MannKind Corp, is that it was founded and largely funded by Al Mann, an engineering genius whose other companies developed the first modern insulin pump (which he sold to Medtronic), the artificial cochlea, and whose latest company has developed a functional artificial retina. Mann is 89 years old and has put more than 10 years into getting Afrezza to market. He understands insulin better than most, having developed the pump, so when he says that Afrezza duplicates first phase insulin, and backs that claim with a billion dollars of his own money, I listen.
Because it is inhaled, Afrezza can not be taken by people who have lung problems or by smokers. It has, however, been tested for safety over a much longer time period than most drugs. This is because Exubera, a completely different formulation, did seem to cause lung cancer. So the FDA insisted on much longer, more rigorous testing for Afrezza.
For now there is no reason for people who are comfortable using fast acting injected insulin who are getting great control with it to switch to Afrezza. But for people who have been putting off moving to meal-time insulin out of a fear of needles, and for those who don't have the necessary skill to work out insulin/carb ratios and carefully dose injected insulin to the carbs in their food, and who are having too many hypo, Afrezza may be very helpful.
And if that activity curve really works out that way in real life, Afrezza might provide a way for people who were just diagnosed with Type 2, who by restoring their lost first phase insulin might be able to totally normalize their blood sugar.
If you do try Afrezza, please let me know how it works for you. Use the email link found on the CONTACT tab at the top of this page and title your email "Afrezza report."
Posted by Jenny at 8:23 AM
|
|
|
Post by babaoriley on Jan 28, 2015 14:36:16 GMT -5
From an Italian press site this morning. Sorry for the poor translation and formating. www.webnews.it/2015/01/28/tecnosfere-afrezza-diabete/Afrezza is an innovative medicine that leveraging Technosphere result of research MannKind , allows the absorption of insulin by inhalation . 1. Could start everything from a small pipette for easy inhalation : his name is Afrezza and at this time is the great hope in the hands of the US MannKind and its shareholders . But hope , beyond the mere computation economic / financial , but also and especially for the world of diabetics . Afrezza, in fact , could be a real revolution for those who have the need for insulin injections : just needles , stop headroom and embarrassment and open road to a simple tool that improves , speeds up and makes more efficient operation . 2. 3. Afrezza and technosphere 4. Everything is based on so-called Technosphere , crystalline micro particles that represent the essence of biomedical research of MannKind . The great innovation that allows this type of technology is the ability to inhale a drug instead of launching the absorption by injection or by ingestion . Inhalation makes for fast absorption and action of the medicine , but it also makes it much easier to do the same . All this , even more so , for those suffering from diabetes and has the need to constantly monitor their situation to take urgent action in case of need Besides diabetes But behind the Technosphere there is much more. Afrezza, in fact, could be a simple platform on which to test the quality of research MannKind. The model, in fact, is potentially applicable to a high number of cases and medicines, which would mean a leap bully in the way that the medicine can intervene in a large number of situations. The Technosphere, in short, could represent a revolution if only these first steps in the world of diabetes should return the desired results. For this there is great attention to the name and on MannKind to Afrezza: patents on guard the hopes of many and a potential leap in the quality of life of millions of people around the world. If you want updates on Afrezza: the revolution of diabetes?, enter your e-mail in the box below: So comforting to know pumping is an international activity! KC, great find!
|
|
|
Post by jpg on Jan 28, 2015 15:32:25 GMT -5
I think we'll be seeing a lot of this from now on. No new information, just new interest. Let the buzz begin...
phlauntdiabetesupdates.blogspot.com/2015/01/afrezza-super-fast-acting-inhaled.html
That isn't just because it's inhaled rather than injected. That's a nice feature that will appeal to the many people with Type 2 who really need insulin but won't start it out of misguided fear of needles. Insulin needles are painless when prescribed correctly. So this is not a good reason to avoid insulin. But people do. We all know far too many people who fit that category. Many end up on dialysis or with amputations.
So Afrezza will be good for needlephobes.
This means it might be an excellent drug for people recently diagnosed and one that is much safer than the drugs like Januvia or Victoza many are being put into at that time, whose dangers I have discussed elsewhere.
What makes me feel that I can trust the company that makes Afrezza, MannKind Corp, is that it was founded and largely funded by Al Mann, an engineering genius whose other companies developed the first modern insulin pump (which he sold to Medtronic), the artificial cochlea, and whose latest company has developed a functional artificial retina. Mann is 89 years old and has put more than 10 years into getting Afrezza to market. He understands insulin better than most, having developed the pump, so when he says that Afrezza duplicates first phase insulin, and backs that claim with a billion dollars of his own money, I listen.
For now there is no reason for people who are comfortable using fast acting injected insulin who are getting great control with it to switch to Afrezza. But for people who have been putting off moving to meal-time insulin out of a fear of needles, and for those who don't have the necessary skill to work out insulin/carb ratios and carefully dose injected insulin to the carbs in their food, and who are having too many hypo, Afrezza may be very helpful.
And if that activity curve really works out that way in real life, Afrezza might provide a way for people who were just diagnosed with Type 2, who by restoring their lost first phase insulin might be able to totally normalize their blood sugar.
Hi Savzak, Great find. This is one of the best articles I have read in a while. The thoughts expressed by the author are an amazing summary of where I think type 1 forward thinkers who haven't yet used it are 'mentally positioned' right now. I highlighted the parts I thought particularly interesting above. The needle phobic thing is, to me anyway, particularly interesting. It is a good example of people living with abnormal situations (needing to inject medication and do complex carb counting etc) thinking it isn't that big a deal (which for many who inject it isn't after they have done it for so long) but then going one step further and 'faulting' (and I am not being judgemental here) others for not embracing needles. Seen from the perspective of someone who has never injected (the vast majority of diabetics) not wanting to stick yourself with needles is not misguided but normal. Seen from the perspective of a type 2 who uses only basal insulin adding mealtime insulin is a huge change in quality of life regardless of the 'non painful needle thing'. Where I think the blogger and I differ is in the scope of 'needlephobes'. People who don't want to inject, carb count, schedule their routines around injections will be classified as 'needlephobes' by Sanofi. I would say needlephobes will more and more be defined as = fear of using needles to inject prandial insulin that is relatively slow in onset, has a hypoglycaemia inducing fat tail, that forces you to carb count and that forces you to schedule you life around the said injections of insulin and not schedule your insulin around your life. Variability and non reproducibility of lifestyle and meals is the enemy of current prandial insulins. vs Inhaling a truly fast acting insulin with minimal tail and without having to carb count or schedule your life around the insulin. You schedule the medication Afrezza around you life. Big liberating difference. The other 3 things that are huge to me are: 1: the realization that the other current therapies are not that great and maybe bad for you. 2. A. Mann's reputation. A guy who has dedicated his life to improving the human condition with a specific focus on diabetics vs AF and BO and a few clueless bloggers. Who do you trust? 3. And last but certainly not least. The first phase thing. Now we are talking a multi billion $ yearly opportunity. Lipitor, Plavix, Afrezza or Afrezza, Lipitor, Plavix? www.forbes.com/sites/simonking/2013/01/28/the-best-selling-drugs-of-all-time-humira-joins-the-elite/
|
|
|
Post by dreamboatcruise on Jan 28, 2015 16:56:22 GMT -5
savzak, phlauntdiabetesupdates article is a great find. Hopefully links and tweets and such get spread far and wide. They solicit email feedback from people that have used Afrezza. Hopefully they can recognize if the FUDsters are sending in false negative testimonials.
|
|
|
Post by gomnkd on Jan 29, 2015 22:30:48 GMT -5
|
|
|
Post by gamblerjag on Jan 29, 2015 23:40:15 GMT -5
Sam.. your famous!!!
|
|
|
Post by gomnkd on Jan 30, 2015 9:36:42 GMT -5
|
|
|
Post by savzak on Jan 30, 2015 16:49:22 GMT -5
|
|
|
Post by dreamboatcruise on Jan 30, 2015 17:03:19 GMT -5
Did that run on CNBC today?
|
|
|
Post by savzak on Jan 30, 2015 17:14:10 GMT -5
Did that run on CNBC today? I don't know. I just found ran across it in a search confined to the past 24 hours. I'm guessing it did not.
|
|